CONMED Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CONMED Corporation on June 17, 2026. The filing discloses the appointment of a new Chief Financial Officer and the departure of interim financial leadership, alongside the terms of the new executive's compensation and severance arrangements.
Key Financial Metrics
The filing does not contain operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data provided relates to the compensation package for the newly appointed Executive Vice President and Chief Financial Officer:
- Annual Base Salary: $650,000
- Target Annual Cash Bonus: 85% of base salary ($552,500)
- One-Time Cash Bonus: $34,750 (contingent on employment through December 31, 2026)
- Initial Equity Grants (Grant Values):
- Stock Options: $575,000
- Restricted Stock Units (RSUs): $1,150,000
- Performance Stock Units (PSUs): $575,000
- Make-Whole RSUs: $1,500,000 (subject to Compensation Committee approval)
Material Changes
The primary material change is the leadership transition in the finance function effective July 15, 2026:
- Appointment: John E. Gallagher appointed as Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer.
- Departure: Patrick Beyer ceases to serve as Interim Principal Financial Officer but remains President and CEO. Kimberly Lockwood ceases to serve as Interim Principal Accounting Officer but remains Interim Corporate Controller.
Outlook, Risks, and Contingencies
Severance Contingencies: The filing details significant severance provisions under the Executive Severance Plan:
- Standard Termination (No Cause): 1.5x base salary + 1.5x average annual incentive awards (prior 2 years) + COBRA health coverage.
- Change in Control Termination: 2.5x base salary + 2.5x average annual incentive awards (prior 3 years) + COBRA health coverage.
- Excise Tax: Payments are subject to a "full or reduced" clause to maximize after-tax benefit if they trigger Section 280G excise taxes.
Management Commentary: The filing notes that Mr. Gallagher brings extensive experience from Certara, Inc., Cue Health Inc., and Becton, Dickinson & Co. No specific business outlook or guidance was provided in this document.
Investor Verification Checklist
- Verify the final approval of the $1,500,000 make-whole RSU grant by the Compensation Committee.
- Review the full text of the Letter Agreement (Exhibit 10.1) for specific performance metrics tied to the annual bonus.
- Confirm the exact transition timeline for the handover of duties from interim officers to Mr. Gallagher on July 15, 2026.
- Monitor future filings for any impact of the new CFO's tenure on financial reporting or strategic direction.